REGENERON PHARMACEUTICALS, INC. - FORM 10-K - EX-23.1 - CONSENT OF PRICEWATERHOUSECOOPERS LLP - February 8, 2018

Attached files

file filename
EX-10.2.15 - RESTRICTED STOCK AWARD AGREEMENT AND NOTICE OF GRANT TO EXECUTIVE OFFICERS - REGENERON PHARMACEUTICALS, INC.regn-ex_10215xar2014ltiprs.htm
EX-32 - CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350 - REGENERON PHARMACEUTICALS, INC.regn-ex_32x12312017x10k.htm
10-K - FORM 10-K - REGENERON PHARMACEUTICALS, INC.regn-123117x10k.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A) - REGENERON PHARMACEUTICALS, INC.regn-ex_312x12312017x10k.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A) - REGENERON PHARMACEUTICALS, INC.regn-ex_311x12312017x10k.htm
EX-21.1 - SUBSIDIARIES OF REGENERON PHARMACEUTICALS, INC. - REGENERON PHARMACEUTICALS, INC.regn-ex_211x12312017x10k.htm
EX-10.2.16 - STOCK OPTION AGREEMENT AND NOTICE OF GRANT (NQ) TO NON-EMPLOYEE DIRECTORS - REGENERON PHARMACEUTICALS, INC.regn-ex_10216xar2014ltipnq.htm
EX-10.2.14 - STOCK OPTION AGREEMENT AND NOTICE OF GRANT (ISO) TO P. ROY VAGELOS - REGENERON PHARMACEUTICALS, INC.regn-ex_10214xar2014ltipis.htm
EX-10.2.13 - STOCK OPTION AGREEMENT AND NOTICE OF GRANT (NQ) TO P. ROY VAGELOS - REGENERON PHARMACEUTICALS, INC.regn-ex_10213xar2014ltipnq.htm
EX-10.2.12 - STOCK OPTION AGREEMENT AND NOTICE OF GRANT (ISO) TO EXECUTIVE OFFICERS - REGENERON PHARMACEUTICALS, INC.regn-ex_10212xar2014ltipis.htm
EX-10.2.11 - STOCK OPTION AGREEMENT AND NOTICE OF GRANT (NQ) TO EXECUTIVE OFFICERS - REGENERON PHARMACEUTICALS, INC.regn-ex_10211xar2014ltipnq.htm


Exhibit 23.1


CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S‑8 (Nos. 333-61132, 333-97375, 333-119257, 333-151941, 333-169569, 333-174863, 333-196799, 333-198794, and 333-218669) of Regeneron Pharmaceuticals, Inc., of our report dated February 8, 2018 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.


/s/ PricewaterhouseCoopers LLP

Florham Park, New Jersey
February 8, 2018




REGENERON PHARMACEUTICALS, INC. Reports